William A Wood1, Jennifer Le-Rademacher2, Karen L Syrjala3, Heather Jim4, Paul B Jacobsen4, Jennifer M Knight2, Muneer H Abidi5, John R Wingard6, Navneet S Majhail7, Nancy L Geller8, J Douglas Rizzo2, Mingwei Fei2, Juan Wu9, Mary M Horowitz2, Stephanie J Lee3. 1. Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. 2. Division of Biostatistics, Psychiatry and Behavioral Medicine,Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 5. Department of Medical Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan. 6. Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, Florida. 7. Taussig Cancer Institute, Cleveland Clinic, Blood and Marrow Transplant Program, Cleveland, Ohio. 8. Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 9. Blood and Marrow Transplant Clinical Trials Network, Milwaukee, Wisconsin.
Abstract
BACKGROUND: In hematopoietic cell transplantation (HCT), current risk adjustment strategies are based on clinical and disease-related variables. Although patient-reported outcomes (PROs) predict mortality in multiple cancers, they have been less well studied within HCT. Improvements in risk adjustment strategies in HCT would inform patient selection, patient counseling, and quality reporting. The objective of the current study was to determine whether pre-HCT PROs, in particular physical health, predict survival among patients undergoing autologous or allogeneic transplantation. METHODS: In this secondary analysis, the authors studied pre-HCT PROs that were reported by 336 allogeneic and 310 autologous HCT recipients enrolled in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902 protocol, a study with broad representation of patients who underwent transplantation in the United States. RESULTS: Among allogeneic HCT recipients, the pre-HCT Medical Outcomes Study Short Form-36 Health Survey (SF-36) physical component summary (PCS) scale independently predicted overall mortality (hazards ratio, 1.40 per 10-point decrease; P<.001) and performed at least as well as currently used, non-PRO risk indices. Survival probability estimates at 1 year for the first, second, third, and fourth quartiles of the baseline PCS were 50%, 65%, 75%, and 83%, respectively. Early post-HCT decreases in PCS were associated with higher overall and treatment-related mortality. When adjusted for patient variables included in the US Stem Cell Therapeutic Outcomes Database model for transplant center-specific reporting, the SF-36 PCS retained independent prognostic value. CONCLUSIONS: PROs have the potential to improve prognostication in HCT. The authors recommend the routine collection of PROs before HCT, and consideration of the incorporation of PROs into risk adjustment for quality reporting.
RCT Entities:
BACKGROUND: In hematopoietic cell transplantation (HCT), current risk adjustment strategies are based on clinical and disease-related variables. Although patient-reported outcomes (PROs) predict mortality in multiple cancers, they have been less well studied within HCT. Improvements in risk adjustment strategies in HCT would inform patient selection, patient counseling, and quality reporting. The objective of the current study was to determine whether pre-HCT PROs, in particular physical health, predict survival among patients undergoing autologous or allogeneic transplantation. METHODS: In this secondary analysis, the authors studied pre-HCT PROs that were reported by 336 allogeneic and 310 autologous HCT recipients enrolled in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902 protocol, a study with broad representation of patients who underwent transplantation in the United States. RESULTS: Among allogeneic HCT recipients, the pre-HCT Medical Outcomes Study Short Form-36 Health Survey (SF-36) physical component summary (PCS) scale independently predicted overall mortality (hazards ratio, 1.40 per 10-point decrease; P<.001) and performed at least as well as currently used, non-PRO risk indices. Survival probability estimates at 1 year for the first, second, third, and fourth quartiles of the baseline PCS were 50%, 65%, 75%, and 83%, respectively. Early post-HCT decreases in PCS were associated with higher overall and treatment-related mortality. When adjusted for patient variables included in the US Stem Cell Therapeutic Outcomes Database model for transplant center-specific reporting, the SF-36 PCS retained independent prognostic value. CONCLUSIONS: PROs have the potential to improve prognostication in HCT. The authors recommend the routine collection of PROs before HCT, and consideration of the incorporation of PROs into risk adjustment for quality reporting.
Authors: Lori S Muffly; Masha Kocherginsky; Wendy Stock; Quynh Chu; Michael R Bishop; Lucy A Godley; Justin Kline; Hongtao Liu; Olatoyosi M Odenike; Richard A Larson; Koen van Besien; Andrew S Artz Journal: Haematologica Date: 2014-05-09 Impact factor: 9.941
Authors: Philippe Armand; Christopher J Gibson; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Jerome Ritz; Mohamed L Sorror; Stephanie J Lee; H Joachim Deeg; Barry E Storer; Frederick R Appelbaum; Joseph H Antin; Robert J Soiffer; Haesook T Kim Journal: Blood Date: 2012-06-18 Impact factor: 22.113
Authors: Jeff A Sloan; Xinghua Zhao; Paul J Novotny; Jason Wampfler; Yolanda Garces; Matthew M Clark; Ping Yang Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Marija Trajkovic-Vidakovic; Alexander de Graeff; Emile E Voest; Saskia C C M Teunissen Journal: Crit Rev Oncol Hematol Date: 2012-03-31 Impact factor: 6.312
Authors: W A Wood; A M Deal; B B Reeve; A P Abernethy; E Basch; S A Mitchell; C Shatten; Y Hie Kim; J Whitley; J S Serody; T Shea; C Battaglini Journal: Bone Marrow Transplant Date: 2013-04-15 Impact factor: 5.483
Authors: Heidi D Klepin; Ann M Geiger; Janet A Tooze; Stephen B Kritchevsky; Jeff D Williamson; Timothy S Pardee; Leslie R Ellis; Bayard L Powell Journal: Blood Date: 2013-04-02 Impact factor: 22.113
Authors: Paul B Jacobsen; Jennifer Le-Rademacher; Heather Jim; Karen Syrjala; John R Wingard; Brent Logan; Juan Wu; Navneet S Majhail; William Wood; J Douglas Rizzo; Nancy L Geller; Carrie Kitko; Edward Faber; Muneer H Abidi; Susan Slater; Mary M Horowitz; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2014-06-06 Impact factor: 5.742
Authors: Jennifer M Knight; Jeffrey M Lyness; Olle Jane Z Sahler; Jane L Liesveld; Jan A Moynihan Journal: Psychoneuroendocrinology Date: 2013-07-08 Impact factor: 4.905
Authors: William A Wood; Margaret K McGinn; Doug Wilson; Allison M Deal; Nandita Khera; Thomas C Shea; Steven M Devine; Frederick R Appelbaum; Mary M Horowitz; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2016-07-29 Impact factor: 5.742
Authors: John R Wingard; William A Wood; Michael Martens; Jennifer Le-Rademacher; Brent Logan; Jennifer M Knight; Paul B Jacobsen; Heather Jim; Navneet S Majhail; Karen Syrjala; J Douglas Rizzo; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2016-10-11 Impact factor: 5.742
Authors: Jennifer M Knight; Karen L Syrjala; Navneet S Majhail; Michael Martens; Jennifer Le-Rademacher; Brent R Logan; Stephanie J Lee; Paul B Jacobsen; William A Wood; Heather S L Jim; John R Wingard; Mary M Horowitz; Muneer H Abidi; Mingwei Fei; Laura Rawls; J Douglas Rizzo Journal: Biol Blood Marrow Transplant Date: 2016-08-23 Impact factor: 5.742
Authors: Li-Wen Huang; Ying Sheng; Charalambos Andreadis; Aaron C Logan; Gabriel N Mannis; Catherine C Smith; Karin M L Gaensler; Thomas G Martin; Lloyd E Damon; Michael A Steinman; Chiung-Yu Huang; Rebecca L Olin Journal: Biol Blood Marrow Transplant Date: 2019-09-05 Impact factor: 5.742